IDXX
IDEXX Laboratories, Inc.$648.70
Sell
Target $479.79
Report: Mar 07, 2026Healthcare • Medical - Diagnostics & Research • Mature CompounderSnapshot
Decision-first overview with recommendation, valuation anchor, and current setup.
Company Overview
Research Snapshot
Price History
Pelican View
Current$648.70-26.0%
Rec: SellConviction: High
Entry Target
N/A
N/A
Fair Value
$479.79
(26% below current)
Stop Loss
N/A
N/A
Position Size
None
Time Horizon
N/A
Key Metrics
Live Snapshot
Market Data
52 Week High$769.98
52 Week Low$356.14
Avg. 3 Month Volume512K
Efficiency
LTM Gross Margin61.8%
LTM EBITDA Margin35.0%
LTM EBIT Margin31.7%
LTM Operating Margin31.6%
LTM ROA31.9%
LTM ROE69.8%
LTM ROIC54.5%
LTM ROCE63.4%
Capital Structure
Market Cap (MM)$44.7B
Enterprise Value (MM)$45.5B
Shares Outstanding79.89M
Total Debt (MM)$948.99M
Cash & Equivalents (MM)$180.07M
LTM Net Debt (MM)$768.92M
LTM Net Debt/EBITDA0.5x
Growth
TTM Rev. Growth10.4%
Last 3-Yr Rev. CAGR8.5%
Last 3-Yr EBITDA CAGR14.2%
Last 3-Yr EPS CAGR17.5%
Valuation
Street Target Price$784.38
LTM EV/Revenue10.6x
LTM EV/Gross Profit17.1x
LTM EV/EBIT33.4x
LTM EV/EBITDA30.2x
LTM P/E42.2x
LTM EV/FCF43.6x
LTM P/FCF42.9x
LTM P/TB15.8x
LTM P/B27.9x
Dividend Yield0.0%
Payout Ratio0.0%
Executive SummarySituation: Current price is $648.7 versus fair value $479.79 (-26.0% expected return), and valuation confidence is stable. Debate: Bull case depends on CEO Succession Execution (May 2026) The transition from Jonathan Mazelsky to Michael Erickson will be a critical test of management continuity. Bear case centers on Moat Erosion via Competitive Disruption Zoetis and Mars are launching rival AI-powered diagnostic tools that could impair IDEXX's pricing power and lead to market share loss in the reference lab segment. Conclusion: Recommendation is Sell with no position, pending a materially better risk/reward setup.
Bull Case
IDEXX maintains a dominant 70% market share in point-of-care diagnostics with a 90% recurring revenue mix that provides high cash flow visibility. The rapid adoption of the inVue Dx analyzer, with 6,400 units placed in 2025, and the expansion of the Cancer Dx platform represent significant long-term growth levers.
Bear Case
The current valuation of 46.5x P/E is excessive given a projected 2% decline in U.S. clinical visits and intensifying competition from Zoetis and Mars. The upcoming CEO transition in May 2026 introduces execution risk during a period of decelerating organic volume growth.
Key Catalysts
Mid-Term (6-18 months)Impact: High
CEO Succession Execution (May 2026) The transition from Jonathan Mazelsky to Michael Erickson will be a critical test of management continui...
Near-Term (0-6 months)Impact: Critical
U.S. Clinical Visit Volume Reports Quarterly data showing a persistent decline in wellness visits will validate the bear thesis that the U.S...
Long-Term (18+ months)Impact: Moderate
IDEXX is at a critical juncture as it navigates a major leadership change while trading at a premium multiple despite clear evidence of slow...
Primary Risks
Concern: High
Moat Erosion via Competitive Disruption Zoetis and Mars are launching rival AI-powered diagnostic tools that could impair IDEXX's pricing po...
Concern: Medium
Macro-Driven Clinical Visit Decline A prolonged economic downturn could lead to a structural reduction in veterinary visits, particularly fo...
Concern: Medium
Stewardship is characterized by strong capital allocation but weak insider alignment. The Governance Outcome Tree suggests: 1. Status Quo: M...
Recent Activity
2025-08-05SEC Filing (8-K)
-5.98%IDEXX Laboratories reports Q2 2025 results with 11% revenue growth and raises full-year guidance
2025-05-01SEC Filing (8-K)
+8.95%IDEXX Laboratories reports Q1 2025 results with 4% revenue growth and updates 2025 guidance.
2024-10-31SEC Filing (8-K)
-9.79%IDEXX Laboratories announces third quarter 2024 results with 7% revenue growth and updates full-year guidance.
2024-05-01SEC Filing (8-K)
-5.02%IDEXX Laboratories reports Q1 2024 revenue growth of 7% with EPS of $2.81, updating full-year guidance
2023-11-02SEC Filing (8-K)
+6.09%IDEXX Laboratories reports Q3 2023 revenue growth of 9% with EPS of $2.53, updating full-year guidance
Valuation Table
9.7/10Decision Grade
Scenario Range
$273
Bear
$393
Base
$461
Bull
$649